FDA Advisory Panel Votes to Allow Claim Regarding Jardiance Cardiovascular Events

A US Food and Drug Administration (FDA) advisory panel has narrowly voted to approve a Jardiance claim that the drug can decrease the risk of cardiovascular death. Jardiance (empagliflozin), an…

More in Health >